Next-generation sequence detects ARAP3 as a novel oncogene in papillary thyroid carcinoma

Related Experiment Video

Updated: Mar 10, 2026

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.4K

Qing-Xuan Wang1, En-Dong Chen1, Ye-Feng Cai1

  • 1Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.

Oncotargets and Therapy
|December 7, 2016
PubMed
Abstract

Insights

The ARAP3 gene plays a significant role in papillary thyroid carcinoma (PTC). Downregulating ARAP3 suppressed PTC cell growth, migration, and invasion, suggesting it as a potential therapeutic target.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Thyroid cancer is a growing global health concern.
  • The molecular mechanisms underlying thyroid cancer remain incompletely understood.
  • The ARAP3 gene has been implicated in various human cancers, but its specific role in thyroid cancer is unclear.

Purpose of the Study:

  • To investigate the role of the ARAP3 gene in the development and progression of papillary thyroid carcinoma (PTC).

Main Methods:

  • Whole exon and whole genome sequencing of PTC samples and adjacent normal tissues.
  • Bioinformatics analysis to identify the role of ARAP3.
  • Functional assays (proliferation, colony formation, migration, invasion) in PTC cell lines with ARAP3 knockdown.

Main Results:

  • ARAP3 was identified as a potentially important gene in thyroid cancer through sequencing and bioinformatics.
  • Downregulation of ARAP3 significantly inhibited proliferation, colony formation, migration, and invasion in PTC cell lines (TPC1, BCPAP, KTC-1).

Conclusions:

  • The ARAP3 gene has significant biological implications in papillary thyroid carcinoma.
  • ARAP3 represents a potential therapeutic target for PTC treatment.
Keywords:
ARAP3next-generation sequenceoncogenepapillary thyroid carcinoma

More Related Videos

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer09:38

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer

Published on: March 28, 2018

12.9K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.7K